Alessandro Galbiati

7PUBLICATIONS
58CO-AUTHORS
Molecular targetsCell development, proliferation and deathCharacterisation of biological macromoleculesRadiation therapy
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (7)

|Jul 13, 2026
The pharmacological profile of ART6043, a first-in-class clinical DNA polymerase theta polymerase domain inhibitor potentiating PARP inhibitor efficacy.

|Dec 08, 2025
Mechanistic insights into the monotherapy and combination potential of FEN1 inhibition in cancer therapy.

Eeson Rajendra, Claudio A Lademann, Bethany Mason

|Dec 18, 2023
Quantitative, titratable and high-throughput reporter assays to measure DNA double strand break repair activity in cells.

Eeson Rajendra, Diego Grande, Bethany Mason

|Mar 27, 2023
Drug-gene Interaction Screens Coupled to Tumor Data Analyses Identify the Most Clinically Relevant Cancer Vulnerabilities Driving Sensitivity to PARP Inhibition.

Kunzah Jamal, Alessandro Galbiati, Joshua Armenia

|Feb 23, 2023
Correction to "Discovery, Characterization, and Structure-Based Optimization of Small-Molecule In Vitro and In Vivo Probes for Human DNA Polymerase Theta".

Martin L Stockley, Giovanni Benedetti, Peter Blencowe

|Jan 23, 2023
Small-Molecule Polθ Inhibitors Provide Safe and Effective Tumor Radiosensitization in Preclinical Models.

Gonzalo Rodriguez-Berriguete, Marco Ranzani, Remko Prevo

Pageof 2

Frequent Collaborators

4 joint publications

Robert A Heald

4 joint publications

Eeson Rajendra

3 joint publications

Mark D Charles

3 joint publications

Claire McWhirter